Table 2 Complete response rates according to the TAC use in SLE patients and these patients after propensity score matching

All patients

n = 572

n = 221

 TAC treatment

  No

431(78.5)

118(21.5)

1.00

1.00

  Yes

141(57.8)

103(42.2)

2.67(1.93,3.7)

2.82(1.89,4.22)

 TAC dose

  No

431(78.5)

118(21.5)

1.00

1.00

  ≤ 2 mg/d

88(61.1)

56(38.9)

2.32(1.57,3.44)

2.42(1.53,3.84)

  3 mg/d

43(57.3)

32(42.7)

2.72(1.65,4.49)

2.92(1.65,5.16)

  ≥ 4 mg/d

10(40.0)

15(60.0)

5.48(2.40,12.51)

5.65(2.35,13.55)

  P for trend

< 0.001

< 0.001

 TAC length of use

  No

431(78.5)

118(21.5)

1.00

1.00

  ≤ 90 days

37(61.7)

23(38.3)

2.27(1.30,3.97)

2.48(1.33,4.63)

  91–180 days

67(58.8)

47(41.2)

2.56(1.68,3.92)

2.60(1.59,4.23)

  > 180 days

37(52.9)

33(47.1)

3.26(1.95,5.43)

3.60(2.02,6.41)

  P for trend

< 0.001

< 0.001

PSM

n = 572

n = 221

 TAC treatment

  No

155(78.3)

43(21.7)

1.00

1.00

  Yes

114(57.6)

84(42.4)

2.66(1.71,4.12)

2.40(1.48,3.88)

 TAC dose

  No

155(78.3)

43(21.7)

1.00

1.00

  ≤ 2 mg/d

74(63.2)

43(36.8)

2.09(1.26,3.47)

1.88(1.09,3.23)

  3 mg/d

33(53.2)

29(46.8)

3.17(1.73,5.79)

2.95(1.53,5.67)

  ≥ 4 mg/d

7(36.8)

12(63.2)

6.18(2.29,16.65)

5.08(1.84,14.04)

  P for trend

< 0.001

< 0.001

 TAC length of use

  No

155(78.3)

43(21.7)

1.00

1.00

  ≤ 90 days

30(65.2)

16(34.8)

1.92(0.96,3.85)

1.64(0.79,3.38)

  91–180 days

52(57.1)

39(42.9)

2.70(1.58,4.62)

2.60(1.47,4.60)

  > 180 days

32(52.5)

29(47.5)

3.27(1.78,5.99)

2.88(1.49,5.54)

  P for trend

< 0.001

< 0.001